Raoul S. Concepcion, MD, FACS, Author at Grand Rounds in Urology

Raoul S. Concepcion, MD, FACS

The Comprehensive Prostate Center

Nashville, Tennessee

Raoul S. Concepcion, MD, is the current Director of The Comprehensive Prostate Center in Nashville, Tennessee, as well as the Chief Urologic Officer for Integra Connect in West Palm Beach, Florida. He was a resident in General Surgery and Urology at Vanderbilt University from 1984-1990, and later served as a Clinical Associate Professor of Urology there. Dr. Concepcion’s clinical interests revolve around advanced prostate and bladder cancer management. He is a past President of LUGPA. Along with two other urologists, founded CUSP, a urologic research consortium in the United States. Additionally, he is an advisor or speaker for many companies, including Dendreon, Pfizer, Astellas, Amgen, Cellay, and Janssen, and is the current editor for Urologists in Cancer Care.

Disclosures:

Articles by Raoul S. Concepcion, MD, FACS

The Effect of Local Antibiogram-Based Augmented Antibiotic Prophylaxis on Infection-Related Complications Following Prostate Biopsy

Posted by Raoul S. Concepcion, MD, FACS | Dec 2019

Raoul S. Concepcion, MD, FACS, and E. David Crawford, MD, discuss a recent study Dr. Concepcion was involved with that looked at antibiotic-augmented prophylaxis based on local antibiograms as a method of reducing infections from prostate biopsies. They discuss the design and rationale of the study and methods for administering the prophylaxis, as well as the results, which showed a 53% reduction in infectious complications compared to historical data.

AR Resistance Mechanisms: Focusing on Variants and Testing

Posted by Raoul S. Concepcion, MD, FACS | Jun 2019

Raoul S. Concepcion, MD, FACS, reviews the role of androgen receptor (AR) resistance mechanisms in recently-approved drugs for metastatic castration-resistant prostate cancer (mCRPC) and disease progression. He then emphasizes the need for better predictive and prognostic biomarkers and the optimization of therapeutic choices in precision medicine.

New Considerations for Oligometastatic Prostate Cancer

Posted by Raoul S. Concepcion, MD, FACS | Jun 2019

Raoul S. Concepcion, MD, FACS, discusses the management of patients with oligometastatic prostate cancer. Currently, there is no standard definition of what defines oligometastatic. Additionally, questions remain about the handling of the primary tumor in this setting, as well as whether therapy directed at the primary has a long term benefit in overall survival.

Upper Tract Urothelial Cancer: What You Need to Know

Posted by Raoul S. Concepcion, MD, FACS | May 2019

Raoul S. Concepcion, MD, FACS, provides an overview of the epidemiology of upper tract urothelial carcinoma (UTUC). He discusses the most recent efforts in improving management for the disease, particularly focusing on neoadjuvant chemotherapy when treating high-grade tumors and nonsurgical ways to combat low-grade UTUC.

AR-V7 Predicts Response in CRPC

Posted by Raoul S. Concepcion, MD, FACS | Apr 2019

Raoul S. Concepcion, MD, FACS, emphasizes the need for more effective biomarkers when determining adequate treatment for patients with castrate-resistant prostate cancer (CRPC). Concurrently, he compares the findings of studies exploring various options, including the AR-V7 splice variant.